Jazz Pharmaceuticals' Ongoing Study of Zanidatamab for HER2-positive Breast Cancer Shows Promise

Jazz Pharmaceuticals is conducting a Phase 3 clinical study to evaluate zanidatamab, a potential new treatment for HER2-positive breast cancer. The study aims to compare the efficacy and safety of zanidatamab with trastuzumab, both combined with chemotherapy. If successful, zanidatamab could offer a new treatment avenue for patients with advanced HER2-positive breast cancer, impacting Jazz Pharmaceuticals' stock performance and investor sentiment.